Involvement of the monoaminergic system in the antidepressant-like activity of chromium chloride in the forced swim test

Journal of Physiology and Pharmacology

Volumn 64, Issue 4, 2013, Pages 493-498

  Piotrowska, A ^a   Siwek, A ^a   Wolak, M ^a   Pochwat, B ^a   Szewczyk, B ^b   Opoka, W ^a   Poleszak, E ^c   Nowak, Gabriel ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Adrenergic antagonist; Adrenergic receptors; Antidepressants; Chromium chloride; Dopaminergic receptors; Forced swim test; Locomotor activity

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CHROMIUM CHLORIDE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; IMIPRAMINE; PRAZOSIN; PROPRANOLOL; REBOXETINE; SULPIRIDE; YOHIMBINE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT LIKE ACTIVITY; ARTICLE; CLIMBING; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; FORCED SWIMMING TEST; IMMOBILITY; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; RAT; SEROTONINERGIC SYSTEM; SWIMMING;

ADRENERGIC ANTAGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; CHLORIDES; CHROMIUM COMPOUNDS; DOPAMINE ANTAGONISTS; DRUG THERAPY, COMBINATION; MALE; MICE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SWIMMING;

EID: 84884946857     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hummel M, Standl E, Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res 2007; 39; 743-751.
2. International Agency for Research on Cancer, World Health Organization, Chromium, Nickel and Welding. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 49. Lyon, France, IARC Press, WHO, 1999.
3. National Toxicology Program, Chromium Hexavalent Compounds, Ninth Report on Carcinogens, US Department of Health and Human Services, 2000.
4. Abdourahman A, Edwards JG. Chromium supplementation improves glucose tolerance in diabetic Goto-Kakizati rats. IUBMB Life 2008; 60: 541-548.
5. Masharani U, Gjerde C, McCoy S, et al. Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity. BMC Endocr Disord 2012; 12: 31.
6. Surani SR, Ratnani I, Guntupalli B, Bopparaju S. Severe insulin resistence treatment with intravenous chromium in septic shock patient. World J Diabetes 2012; 3: 170-173.
7. Katon W, Fan MY, Unutzer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potential lethal combination. J Gen Intern Med 2008; 23: 1571-1575.
8. Leonard EE. Effects of depression on work loss and disability bed days in individuals with diabetes. Diab Care 2004; 27: 1751-1753.
9. Davidson JR, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003; 53: 261-264.
10. Docherty JP, Sack DA, Hoffman M, Finch M, Komorowski JR. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiat Pract 2005; 11: 302-314.
11. McCarty MF. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression-an adjuvant role for chromium picolinate? Med Hypotheses 1994; 43: 247-252.
12. McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry 1999; 60: 237-240.
13. McLeod MN, Golden RN. Chromium treatment of depression. Int J Neuropsychopharmacol 2000; 3: 311-314.
14. 2Areceptors. Psychopharmacology (Berl) 2002; 159: 432-436.
15. Khanam R, Pillai KK. Effect of chromium picolinate on modified forced swimming test in diabetic rats: involvement of serotonergic pathways and potassium channels. Basic Clin Pharmacol Toxicol 2006; 98: 155-159.
16. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.
17. Coppen AJ. Biochemical aspects of depression. Int Psychiat Clin 1969; 6: 53-81.
18. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl) 1977; 53: 309-314.
19. 1Aand beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 2000; 15: 113-135.
20. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn 1977; 229: 327-336.
21. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioral despair in rat: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978; 47: 379-391.
22. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995; 121: 66-72.
23. Iovieno N, Dalton ED, Fava M, Mischoulon D. Second-tier natural antidepressanta: review and critique. J Affect Disord 2011; 130: 343-357.
24. Piotrowska A, Mlyniec K, Siwek A, Dybala M, Opoka W, Poleszak E, Nowak G. Antidepressant-like effect of chromium chloride in the mouse force swim test: involvement of glutamatergic and serotonergic receptors. Pharmacol Rep 2008; 60: 991-995.
25. Franklin M, Odontiadis J. Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat. Pharmacopsychiatry 2003; 36: 176-180.
26. Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120536. doi: 10.1098/rstb.2012.0536.
27. Czubak A, Nowakowska E, Golembiowska K, Kus K, Burda K, Metelska J. Effect of venlafaxine and nicotine on the level of neurotransmitters and metabolites in rat brains. J Physiol Pharmacol 2010; 61: 339-346.
28. Ribback S, Pavlovic D, Herbst D, et al. Effects of amitriptyline, fluoxetine, tranylcypromine and venlafaxine on rat vascular smooth muscle in vitro-the role of the endothelium. J Physiol Pharmacol 2012; 63: 119-125.
29. Javelot H, Messaoudi M, Garnier S, Rougeot C. Human opiorphin is a naturally occurring antidepressant acting selectively on encephalin-dependent d-opioid pathways. J Physiol Pharmacol 2010; 61: 355-362.